


# *Metal-Catalyzed Asymmetric Cross-Coupling Reactions*

**181215\_LS\_Daiki\_Kamakura**



# *Cross-Coupling Reactions Using $sp^3$ -Substrates*

$sp^2$ - $sp^2$  cross coupling



$\text{M} = \text{BR}_2, \text{ZnR}, \text{SnR}_3, \text{SiR}_3, \dots; \text{X} = \text{I}, \text{Br}, \text{Cl}, \text{OTf}, \dots$



$sp^3$ - $sp^2$  cross coupling



$sp^3$ - $sp^3$  cross coupling




# Strategies for Asymmetric Cross-Coupling Reactions




# Contents

## 1. Catalytic Enantioconvergent Coupling of Secondary and Tertiary Electrophiles with Olefins (Fu, 2018)




## 2. Enantiodivergent Pd-Catalyzed C–C Bond Formation Enabled through Ligand Parameterization (Sigman, Biscoe, 2018)




# Contents

## 1. Catalytic Enantioconvergent Coupling of Secondary and Tertiary Electrophiles with Olefins (Fu, 2018)




## 2. Enantiodivergent Pd-Catalyzed C–C Bond Formation Enabled through Ligand Parameterization (Sigman, Biscoe, 2018)



# Fu's Previous Works


- Enantioselective cross coupling of propargyl bromide with diphenylzinc



Smith, S. W.; Fu, G. C. *J. Am. Chem. Soc.* **2008**, *130*, 12645.

Schley, N. D.; Fu, G. C. *J. Am. Chem. Soc.* **2014**, *136*, 16588.


- Control of Vicinal Stereocenters through Nickel-Catalyzed Alkyl-Alkyl Cross-Coupling



Mu, X.; Shibata, Y.; Makida, Y.; Fu, G. C. *Angew. Chem. Int. Ed.* **2017**, *56*, 5821.

# Construction of Quaternary Carbon Center


- Enantioselective cross coupling of *tert*-haloalkane




$L^*$  = chiral ligand

It is difficult to quaternary carbon center by cross-coupling reaction

- Reported methods




Tsuji, T.; Yorimitsu, H.; Oshima, K. *Angew. Chem. Int. Ed.*, **2002**, *41*, 4147.




Zultanski, S. L.; Fu, G. C. *J. Am. Chem. Soc.* **2013**, *135*, 624.

→ Asymmetric construction of quaternary carbon center has not been achieved.


# Ni-Catalyzed Reaction of sec-Bromide with Olefin



Entry	variation from the “standard conditions”	yield	ee (%)
1	under air	66%	94%
2	with H <sub>2</sub> O (1.0 eq.)	78%	95%
3	gram scale	88%	94%




# Design of Substrate




In order to reduce steric hindrance in the vicinity of the reactive site, cyclic substrate was designed.

# Ni-Catalyzed Reaction of *tert*-Bromide with Olefin




# *Transformations of Obtained Compound*




# Initially Proposed Mechanism

- Initially proposed mechanism




- Reaction with alkylsilane




# Mechanistic Study


- Reaction of complex A with *tert*-bromide




<possible mechanism to give alkyl-Ni<sup>II</sup>>



# *Proposed Catalytic Cycle*




# Short Summary




# Contents

## 1. Catalytic Enantioconvergent Coupling of Secondary and Tertiary Electrophiles with Olefins (Fu, 2018)




## 2. Enantiodivergent Pd-Catalyzed C–C Bond Formation Enabled through Ligand Parameterization (Sigman, Biscoe, 2018)




# Cross-Coupling of Chiral Boronic Esters

- Stereoretentive reaction




Imao, D.; Veronique, G.; Laberge, S.; Crudden, C. M. *J. Am. Chem. Soc.* **2009**, *131*, 5024.


- Stereoretentive reaction



Ohmura, T.; Awano, T.; Suginome, M. *J. Am. Chem. Soc.* **2010**, *132*, 13191.




# Cross-Coupling of Chiral Boronic Esters



Li, L.; Zhao, S.; Joshi-Pangu, A.; Diane, M.; Biscoe, M. R. *J. Am. Chem. Soc.* **2014**, 136, 14027.


The factors controlling the dominant mechanism of transmetalation are not understood.



Aim of this research:

- Development of the ligand-controlled enatiodivergent cross-coupling reaction
- To reveal the factors that control the transfer of stereochemistry

# *Effects of the Substituent and Ligand*




Z	$\sigma_{\text{para}}$	ee ( $\text{L} = \text{Pt-Bu}_3$ )	L	solid angle	ee ( $\text{Z} = \text{CO}_2\text{Et}$ )
OMe	-0.27	-91%	Pt-Bu <sub>3</sub>	150°	-79%
Me	-0.17	-89%	PAd <sub>2</sub> n-Bu	150°	+4%
CO <sub>2</sub> Et	0.45	-79%	PPh <sub>3</sub>	126°	+12%
CF <sub>3</sub>	0.54	-72%	Pt-Bu <sub>2</sub> Ph	145°	+21%
CN	0.66	-67%	Po-tol <sub>3</sub>	153°	+65%

Ad = adamantyl

→ No obvious correlation was observed between these results and the steric properties (solid angle).

# General Scheme of Model Development




<sup>a</sup> A conformational search was performed for all phosphines using OPLS3 force field and low frequency-mode conformational search. Conformers within 15kcal/mol were considered for further computations.

<sup>b</sup> All structures were fully optimized at the PBE0/6-31+G(d) level and frequency analysis was performed at the same level.

<sup>c</sup> Multivariate model development was performed using MATLAB R2017a with forward stepwise linear regression.


Xiao, S.; Gensch, T.; Murray, B.; Niemeyer, Z. L.; Sigman, M. S.; Biscoe, M. *Science*, **2018**, 362, 670. <sup>19</sup>

# Experimental Workflow




<steric properties>

%V<sub>bur</sub>




Sterimol values




\* obtain four kinds of values  
(min, max, Boltz, MC) with one  
property


# Initial Investigations



# *Epimerization via $\beta$ -Hydride Elimination*




# Enantiospecificity Trend




only ligands providing high selectivity were further investigated (>30% ee)




A correlation between enantioselectivity and  $V_{\min}$  was observed




$V_{\min}^{\text{Boltz}}$ : Minimum of the molecular electrostatic potential in the phosphorus lone pair region



# Enantiospecificity Trend




only ligands providing high selectivity were further investigated (>30%ee)




A correlation between enantioselectivity and  $V_{\min}$  was observed





New Ligands were designed



$V_{\min}^{\text{Boltz}}$ : Minimum of the molecular electrostatic potential in the phosphorus lone pair region



# New Ligand Design



$\text{Ar}^1 = 2,6\text{-di-MeOC}_6\text{H}_3$

10  
 $V_{\min}^{\text{Boltz}} = -0.040$

11  
 $-0.030$

12  
 $-0.055$




$\text{Ar}^1 = 2,4,6\text{-tri-}i\text{-PrC}_6\text{H}_2$

13  
 $-0.038$

14  
 $-0.029$


15  
 $-0.052$

# Effects of New Ligands




<b>Ar<sup>1</sup></b> = <b>2,6-di-MeOC<sub>6</sub>H<sub>3</sub></b>	<b>10</b>	<b>11</b>	<b>12</b>
	$V_{\min}^{\text{Boltz}} = -0.040$	<b>-0.030</b>	<b>-0.055</b>
	75% ee	90% ee	35% ee
<b>Ar<sup>1</sup></b> = <b>2,4,6-tri-i-PrC<sub>6</sub>H<sub>2</sub></b>	<b>7.4 : 1 (b: l)</b>	<b>45 : 1 (b: l)</b>	<b>1 : 2.1 (b: l)</b>
	<b>13</b>	<b>14</b>	<b>15</b>
	<b>-0.038</b>	<b>-0.029</b>	<b>-0.052</b>
<b>Ar<sup>1</sup></b> = <b>2,4,6-tri-i-PrC<sub>6</sub>H<sub>2</sub></b>	90% ee	90% ee	81% ee
	<b>43 : 1 (b: l)</b>	<b>69 : 1 (b: l)</b>	<b>(11 : 1 b: l)</b>


# Substrate Scope



# *Limitation of the Reaction*



# Multivariate Regression Analysis




Additionally, 24  
ligands were tested

17 training sets


+

7 variations



-90% ~ +98% ee


$\Delta\Delta G^\ddagger$  range: 5.5 kcal/mol



Multivariate  
linear regression

omit smaller  
4 ligands ( $B_1^{\text{Boltz}} < 4$ )


# Results of Multivariate Linear Regression





$E_{\sigma^*(\text{P-C})\text{ave}}$  ... The average energy of the P-C antibonding ( $\sigma^*$ ) orbitals

$ELP(\text{P})$  ... the energy of the lone pair orbital of phosphorus



It was found that enantioselectivity depends on the electrical properties of the ligands



# Proposed Reaction Mechanism



# Summary




# *Appendix*

## **Branched : linear ratio**



*Branched:linear ratios and yields for ligands used in Figure 2. (see S46 for ligands)*

ligand	yield (%)	branched/linear	ligand	yield (%)	branched/linear
<b>1</b>	62	2.5	<b>S1</b>	54	2.0
<b>2</b>	24	2.5	<b>S2</b>	97	27.8
<b>3</b>	75	1.1	<b>S3</b>	78	1.5
<b>4</b>	17	1.1	<b>S4</b>	12	2.1
<b>5</b>	27	0.09	<b>S5</b>	19	1.6
<b>6</b>	12	0.09	<b>S6</b>	17	1.1
<b>7</b>	41	2.2	<b>S7</b>	46	1.0
<b>8</b>	67	20.2	<b>S8</b>	11	1.1
<b>9</b>	87	190	<b>S9</b>	69	0.8
<b>10</b>	57	7.4	<b>S10</b>	14	0.6
<b>11</b>	63	45	<b>S11</b>	70	0.8
<b>12</b>	25	0.5	<b>S12</b>	24	0.07
<b>13</b>	63	43	<b>S13</b>	67	3.6
<b>14</b>	50	69	<b>S14</b>	77	0.3
<b>15</b>	53	11	<b>S15</b>	97	0.1
			<b>S16</b>	50	69

# The Ratio of Branched Compounds

















# *Preparation of Substrates*




Stymiest, J. L.; Dutheuil, G. D.; Mahmood, A.; Aggarwal, V. K. *Angew. Chem. Int. Ed.* **2007**, *46*, 7491.  
Homologation reaction using lithiated carbamate: 140614\_LS\_Keiichiro\_Fukushima

# Ligand Set (1)




## *Ligand Set (2)*



# Data Set

Figure S1. Left: “Full data set” model from Figure 4B. Right: “20 ligand set” from Figure 4D.



# Parameters (1)

**Table S4. Parameters describing steric properties of the ligands.**

No.	Ligand	% <i>V</i> <sub>bur</sub> in %			Sterimol <i>B</i> <sub>1</sub>			Sterimol <i>B</i> <sub>5</sub>			Sterimol <i>L</i>			<i>SolidA.</i> Boltz				
		Boltz	MC	Min	Max	Boltz	MC	Min	Max	Boltz	MC	Min	Max					
<b>1</b>	PoTol <sub>3</sub>	41.1	41.1	33.3	41.1	4.47	4.47	4.32	4.47	6.35	6.35	6.35	6.65	6.99	6.98	6.98	7.88	153
<b>2</b>	PhSPhos	51.8	51.8	30.6	51.8	4.32	4.32	4.32	4.61	7.16	7.16	6.83	7.16	7.29	7.29	7.29	9.90	179
<b>3</b>	SPhos	55.0	55.9	32.9	60.3	4.52	4.38	4.33	4.93	7.24	7.30	6.55	7.30	7.72	7.72	7.70	10.3	192
<b>4</b>	PPh <sub>3</sub>	28.8	28.8	28.8	28.8	4.27	4.27	4.27	4.27	6.34	6.34	6.34	6.34	7.12	7.12	7.12	7.12	126
<b>5</b>	PEt <sub>3</sub>	27.4	27.6	25.6	28.0	3.25	3.39	2.98	3.39	4.81	4.80	4.77	4.87	5.93	5.74	5.74	6.73	124
<b>6</b>	PMe <sub>3</sub>	22.3	22.3	22.3	22.3	2.96	2.96	2.96	2.96	3.47	3.47	3.47	3.47	5.74	5.74	5.74	5.74	106
<b>7</b>	P'Bu <sub>2</sub> neopentyl	40.8	40.8	34.7	40.8	3.99	3.99	3.93	3.99	6.18	6.18	5.56	6.18	6.64	6.64	6.64	7.88	158
<b>8</b>	P'Bu <sub>3</sub>	36.6	36.6	36.6	36.6	4.04	4.04	4.04	4.04	4.87	4.87	4.87	4.87	6.62	6.62	6.62	6.62	150
<b>9</b>	PAd <sub>3</sub>	37.2	37.2	37.2	37.2	5.21	5.21	5.21	5.21	6.88	6.88	6.88	6.88	7.34	7.34	7.34	7.34	157
<b>10</b>	CF <sub>3</sub> PhSPhos	51.9	51.9	29.6	51.9	4.59	4.59	4.59	5.24	7.99	7.99	7.99	8.17	7.96	7.96	7.96	9.44	180
<b>11</b>	di-CF <sub>3</sub> PhSPhos	50.7	52.6	30.7	52.6	5.17	5.16	5.16	5.30	7.74	7.74	7.68	7.74	8.77	8.65	8.65	10.0	187
<b>12</b>	<i>o</i> TolSPhos	59.6	59.7	39.6	62.2	4.47	4.47	4.22	4.71	7.17	7.17	6.57	7.43	7.21	7.20	7.20	9.95	196
<b>13</b>	CF <sub>3</sub> PhXPhos	55.6	55.6	31.5	55.6	5.41	5.41	4.89	5.41	8.03	8.03	8.03	8.19	7.94	7.94	7.94	11.5	198
<b>14</b>	di-CF <sub>3</sub> PhXPhos	56.8	56.8	31.1	56.8	5.92	5.92	5.68	5.92	7.76	7.76	7.76	7.81	8.89	8.89	8.89	11.5	206
<b>15</b>	PhXPhos	55.7	56.0	32.1	58.2	4.36	4.36	4.36	4.69	7.45	7.45	7.30	7.64	7.33	7.33	7.33	11.3	199
<b>S1</b>	3-C9	51.3	51.2	30.5	51.8	4.32	4.30	4.30	4.57	7.23	6.89	6.89	8.13	7.31	7.27	7.27	9.85	178
<b>S2</b>	P'Bu <sub>2</sub> Ph	35.7	35.7	35.7	35.7	3.93	3.93	3.93	3.93	6.43	6.43	6.43	6.43	7.46	7.46	7.46	7.46	145
<b>S3</b>	RuPhos	57.2	59.7	52.4	59.7	4.59	4.35	4.34	4.95	8.50	8.78	8.12	8.78	7.72	7.74	7.54	7.75	203
<b>S4</b>	P(2-OMe-Ph) <sub>3</sub>	37.2	37.4	33.2	42.3	4.98	5.07	4.28	5.07	6.38	6.36	6.36	6.57	7.09	6.92	6.92	8.74	149
<b>S5</b>	P(4-CF <sub>3</sub> -Ph) <sub>3</sub>	28.8	28.8	28.8	28.8	5.31	5.31	5.30	5.31	8.04	8.04	8.04	8.04	7.70	7.88	7.51	7.88	127
<b>S6</b>	P <sub>p</sub> Tol <sub>3</sub>	28.8	28.8	28.8	28.8	4.91	4.91	4.91	4.91	7.45	7.45	7.45	7.45	7.28	7.28	7.28	7.28	126
<b>S7</b>	XPhos	57.4	57.2	55.7	62.9	4.90	4.97	4.32	4.97	7.52	7.50	7.34	7.87	7.66	7.67	7.57	7.71	205
<b>S8</b>	monoXantphos	32.4	32.4	30.3	32.4	4.21	4.21	4.11	4.21	8.67	8.70	7.02	8.70	7.35	7.29	7.29	11.5	140
<b>S9</b>	CyJohnPhos	47.9	47.6	34.6	54.7	4.40	4.39	4.08	4.44	6.75	6.75	6.69	6.78	7.75	7.73	7.73	10.2	173
<b>S10</b>	PBnPh <sub>2</sub>	30.7	30.7	27.2	32.1	3.34	3.36	3.25	3.40	7.33	7.38	6.46	7.47	7.72	7.52	7.52	9.96	134
<b>S11</b>	CPhos	56.9	59.7	50.9	63.0	4.89	4.97	3.47	5.00	7.69	7.88	7.25	7.97	7.64	7.66	7.62	7.86	207
<b>S12</b>	P'Bu <sub>3</sub>	26.4	26.1	25.6	33.3	3.60	3.53	3.53	4.16	7.21	7.35	6.33	7.35	8.52	8.75	6.88	8.75	121
<b>S13</b>	PAd <sub>2</sub> 'Bu	35.8	34.7	33.4	42.4	4.67	4.64	4.11	4.98	7.15	7.42	6.81	7.42	7.48	7.48	7.46	8.59	150
<b>S14</b>	PCy <sub>3</sub>	32.3	32.1	30.8	42.9	4.41	4.41	3.87	4.62	6.75	6.77	6.45	6.83	7.66	7.71	7.38	7.82	139
<b>S15</b>	P'Bu <sub>2</sub> Me	31.9	31.9	31.9	31.9	3.31	3.31	3.31	3.31	4.87	4.87	4.87	4.87	6.63	6.63	6.63	6.63	135
<b>S16</b>	P'Bu <sub>2</sub> Cy	36.1	36.1	35.1	40.5	3.97	3.97	3.97	4.06	6.56	6.56	5.89	6.78	7.45	7.45	6.67	7.45	147
<b>S17</b>	P'BuCy <sub>2</sub>	33.9	33.6	32.9	43.4	4.06	3.99	3.85	4.24	6.74	6.80	6.02	6.80	7.51	7.51	6.71	7.61	144

# Parameters (2)

**Table S5. Parameters describing electronic properties of the ligands, Pt. 1.**

No.	Ligand	$E_{\text{HOMO}}$ in Hartree				$E_{\text{LUMO}}$ in Hartree				$V_{\text{min}}$ in kcal/mol				$\sigma(^3\text{P})$ in ppm			
		Boltz	MC	Min	Max	Boltz	MC	Min	Max	Boltz	MC	Min	Max	Boltz	MC	Min	Max
<b>1</b>	PoTol <sub>3</sub>	-0.258	-0.258	-0.258	-0.250	0.000	0.000	-0.006	0.000	-27.6	-27.6	-32.9	-27.6	343	343	306	343
<b>2</b>	PhSPhos	-0.253	-0.253	-0.253	-0.213	0.004	0.004	-0.019	0.004	-35.3	-35.3	-35.3	-35.1	325	325	302	325
<b>3</b>	SPhos	-0.251	-0.251	-0.256	-0.247	0.014	0.012	0.011	0.017	-43.3	-43.4	-44.7	-41.2	325	325	284	355
<b>4</b>	PPh <sub>3</sub>	-0.265	-0.265	-0.265	-0.225	0.000	0.000	-0.024	0.000	-29.9	-29.9	-29.9	-29.9	320	320	320	320
<b>5</b>	PEt <sub>3</sub>	-0.269	-0.271	-0.271	-0.267	0.061	0.063	0.058	0.063	-38.1	-37.6	-38.9	-37.5	341	338	338	345
<b>6</b>	PMe <sub>3</sub>	-0.274	-0.274	-0.274	-0.274	0.065	0.065	0.065	0.065	-36.6	-36.6	-36.6	-36.6	384	384	384	384
<b>7</b>	P'Bu <sub>2</sub> neopentyl	-0.259	-0.259	-0.259	-0.219	0.052	0.052	0.035	0.052	-39.1	-39.1	-43.2	-39.1	301	301	266	301
<b>8</b>	P'Bu <sub>3</sub>	-0.255	-0.255	-0.255	-0.255	0.059	0.059	0.059	0.059	-41.9	-41.9	-41.9	-41.9	256	256	256	256
<b>9</b>	PAd <sub>3</sub>	-0.247	-0.247	-0.247	-0.247	0.038	0.038	0.038	0.038	-44.6	-44.6	-44.6	-44.6	253	253	253	253
<b>10</b>	CF <sub>3</sub> PhSPhos	-0.271	-0.271	-0.271	-0.228	-0.025	-0.025	-0.047	-0.025	-25.0	-25.0	-25.0	-24.1	324	324	308	324
<b>11</b>	di-CF <sub>3</sub> PhSPhos	-0.281	-0.281	-0.285	-0.281	-0.041	-0.041	-0.041	-0.041	-18.8	-18.9	-18.9	-17.9	322	323	308	323
<b>12</b>	<i>o</i> TolSPhos	-0.250	-0.250	-0.256	-0.210	0.005	0.005	-0.018	0.005	-34.7	-34.7	-36.2	-31.7	341	341	315	345
<b>13</b>	CF <sub>3</sub> PhXPhos	-0.276	-0.276	-0.278	-0.276	-0.032	-0.031	-0.033	-0.031	-23.6	-23.6	-23.6	-21.5	331	331	294	331
<b>14</b>	di-CF <sub>3</sub> PhXPhos	-0.286	-0.286	-0.289	-0.286	-0.047	-0.047	-0.048	-0.047	-18.1	-18.1	-18.1	-14.9	330	330	296	330
<b>15</b>	PhXPhos	-0.260	-0.260	-0.260	-0.256	-0.008	-0.007	-0.010	-0.007	-32.8	-32.8	-35.7	-32.1	331	331	293	332
<b>S1</b>	3-C9	-0.249	-0.250	-0.251	-0.206	-0.016	-0.016	-0.038	-0.015	-36.1	-37.1	-37.1	-33.6	329	330	302	330
<b>S2</b>	P'Bu <sub>2</sub> Ph	-0.263	-0.263	-0.263	-0.263	0.005	0.005	0.005	0.005	-38.8	-38.8	-38.8	-38.8	278	278	278	278
<b>S3</b>	RuPhos	-0.251	-0.251	-0.255	-0.249	0.015	0.014	0.009	0.018	-44.7	-44.6	-46.1	-43.6	326	326	324	337
<b>S4</b>	P(2-OMe-Ph) <sub>3</sub>	-0.245	-0.244	-0.250	-0.204	0.011	0.011	-0.015	0.011	-42.4	-42.7	-42.7	-37.2	351	352	330	353
<b>S5</b>	P(4-CF <sub>3</sub> -Ph) <sub>3</sub>	-0.297	-0.297	-0.297	-0.254	-0.038	-0.038	-0.060	-0.038	-13.6	-13.6	-13.6	-13.6	320	320	320	320
<b>S6</b>	PpTol <sub>3</sub>	-0.256	-0.256	-0.256	-0.217	0.006	0.006	-0.018	0.006	-32.9	-32.9	-32.9	-32.9	323	323	323	323
<b>S7</b>	XPhos	-0.257	-0.257	-0.262	-0.217	0.002	0.003	-0.026	0.004	-40.2	-40.1	-41.9	-38.2	329	329	329	343
<b>S8</b>	monoXantphos	-0.258	-0.258	-0.261	-0.221	-0.002	-0.001	-0.032	-0.001	-32.6	-32.6	-32.6	-31.9	328	328	309	328
<b>S9</b>	CyJohnPhos	-0.257	-0.256	-0.262	-0.256	0.000	0.000	-0.001	0.000	-39.5	-39.3	-40.7	-39.3	333	333	285	345
<b>S10</b>	PBnPh <sub>2</sub>	-0.268	-0.269	-0.269	-0.229	0.000	0.001	-0.023	0.001	-30.4	-30.7	-30.9	-28.7	322	323	310	323
<b>S11</b>	CPhos	-0.250	-0.249	-0.255	-0.248	0.005	0.005	0.004	0.008	-42.0	-40.6	-45.8	-40.6	323	323	314	337
<b>S12</b>	P'Bu <sub>3</sub>	-0.266	-0.265	-0.269	-0.264	0.054	0.054	0.051	0.061	-39.2	-39.3	-39.6	-37.5	350	350	346	366
<b>S13</b>	PAd <sub>2</sub> 'Bu	-0.255	-0.255	-0.255	-0.250	0.043	0.042	0.040	0.044	-42.1	-42.3	-43.8	-39.5	293	291	285	312
<b>S14</b>	PCy <sub>3</sub>	-0.258	-0.258	-0.261	-0.252	0.054	0.054	0.049	0.058	-41.6	-41.7	-43.9	-39.0	306	304	285	341
<b>S15</b>	P'Bu <sub>2</sub> Me	-0.262	-0.262	-0.262	-0.262	0.057	0.057	0.057	0.057	-40.0	-40.0	-40.0	-40.0	309	309	309	309
<b>S16</b>	P'Bu <sub>2</sub> Cy	-0.254	-0.254	-0.256	-0.253	0.056	0.056	0.055	0.057	-42.2	-42.2	-42.7	-40.5	268	268	268	294
<b>S17</b>	P'BuCy <sub>2</sub>	-0.257	-0.258	-0.259	-0.253	0.054	0.054	0.051	0.056	-41.7	-41.5	-43.0	-39.2	290	292	277	323



# Parameters (3)

**Table S6. Parameters describing electronic properties of the ligands, Pt. 2.**

No.	Ligand	NBO( <i>P</i> )				<i>E</i> <sub>L<sub>P</sub>(P)</sub> in Hartree		<i>E</i> <sub>σ*(P-C)min</sub> in Hartree		<i>E</i> <sub>σ*(P-C)avg</sub> in Hartree	
		Boltz	MC	Min	Max	Boltz	MC	Boltz	MC	Boltz	MC
<b>1</b>	PoTol <sub>3</sub>	0.819	0.819	0.819	0.836	-0.398	-0.398	0.261	0.261	0.261	0.261
<b>2</b>	PhSPhos	0.841	0.841	0.837	0.841	-0.398	-0.398	0.262	0.262	0.263	0.263
<b>3</b>	SPhos	0.829	0.831	0.764	0.831	-0.396	-0.394	0.241	0.242	0.251	0.252
<b>4</b>	PPh <sub>3</sub>	0.829	0.829	0.829	0.829	-0.406	-0.406	0.254	0.254	0.254	0.254
<b>5</b>	PEt <sub>3</sub>	0.764	0.762	0.758	0.768	-0.421	-0.425	0.234	0.235	0.235	0.235
<b>6</b>	PM <sub>3</sub>	0.764	0.764	0.764	0.764	-0.424	-0.424	0.243	0.243	0.243	0.243
<b>7</b>	P'Bu <sub>2</sub> neopentyl	0.788	0.788	0.788	0.794	-0.400	-0.400	0.212	0.212	0.221	0.221
<b>8</b>	P'Bu <sub>3</sub>	0.785	0.785	0.785	0.785	-0.387	-0.387	0.207	0.207	0.207	0.207
<b>9</b>	PAd <sub>3</sub>	0.839	0.839	0.839	0.839	-0.369	-0.369	0.220	0.220	0.220	0.220
<b>10</b>	CF <sub>3</sub> PhSPhos	0.852	0.852	0.847	0.852	-0.417	-0.417	0.243	0.243	0.244	0.244
<b>11</b>	di-CF <sub>3</sub> PhSPhos	0.863	0.864	0.849	0.864	-0.431	-0.432	0.226	0.226	0.229	0.229
<b>12</b>	<i>o</i> TolSPhos	0.834	0.834	0.827	0.841	-0.393	-0.393	0.266	0.266	0.268	0.268
<b>13</b>	CF <sub>3</sub> PhXPhos	0.854	0.854	0.844	0.854	-0.422	-0.422	0.237	0.237	0.238	0.238
<b>14</b>	di-CF <sub>3</sub> PhXPhos	0.865	0.865	0.853	0.865	-0.437	-0.437	0.220	0.220	0.223	0.223
<b>15</b>	PhXPhos	0.843	0.843	0.839	0.849	-0.404	-0.403	0.253	0.253	0.257	0.257
<b>S1</b>	3-C9	0.843	0.843	0.838	0.843	-0.400	-0.400	0.258	0.258	0.260	0.260
<b>S2</b>	P'Bu <sub>2</sub> Ph	0.804	0.804	0.804	0.804	-0.388	-0.388	0.211	0.211	0.229	0.229
<b>S3</b>	RuPhos	0.827	0.830	0.789	0.837	-0.396	-0.394	0.241	0.242	0.251	0.251
<b>S4</b>	P(2-OMe-Ph) <sub>3</sub>	0.890	0.892	0.851	0.892	-0.393	-0.394	0.269	0.269	0.269	0.269
<b>S5</b>	P(4-CF <sub>3</sub> -Ph) <sub>3</sub>	0.841	0.841	0.841	0.841	-0.436	-0.436	0.224	0.224	0.224	0.224
<b>S6</b>	PpTol <sub>3</sub>	0.829	0.829	0.829	0.829	-0.400	-0.400	0.261	0.261	0.261	0.261
<b>S7</b>	XPhos	0.827	0.829	0.783	0.829	-0.403	-0.402	0.231	0.231	0.242	0.242
<b>S8</b>	monoXantphos	0.848	0.848	0.836	0.848	-0.405	-0.405	0.252	0.252	0.257	0.257
<b>S9</b>	CyJohnPhos	0.822	0.825	0.793	0.825	-0.403	-0.401	0.233	0.234	0.243	0.243
<b>S10</b>	PBnPh <sub>2</sub>	0.827	0.829	0.822	0.829	-0.420	-0.421	0.217	0.217	0.240	0.240
<b>S11</b>	CPhos	0.837	0.846	0.793	0.846	-0.398	-0.398	0.238	0.240	0.247	0.248
<b>S12</b>	P'Bu <sub>3</sub>	0.786	0.786	0.772	0.792	-0.412	-0.411	0.238	0.238	0.239	0.239
<b>S13</b>	PAd <sub>2</sub> 'Bu	0.838	0.841	0.822	0.843	-0.388	-0.387	0.229	0.230	0.234	0.234
<b>S14</b>	PCy <sub>3</sub>	0.812	0.814	0.761	0.823	-0.397	-0.396	0.231	0.231	0.236	0.236
<b>S15</b>	P'Bu <sub>2</sub> Me	0.794	0.794	0.794	0.794	-0.402	-0.402	0.213	0.213	0.223	0.223
<b>S16</b>	P'Bu <sub>2</sub> Cy	0.808	0.808	0.765	0.808	-0.384	-0.384	0.215	0.215	0.221	0.221
<b>S17</b>	P'BuCy <sub>2</sub>	0.806	0.804	0.746	0.817	-0.393	-0.397	0.214	0.213	0.227	0.227

# Initial Investigations

**Table S-1. Effect of Reaction Parameters.**



Entry	Variation from the "standard conditions"	ee (%)	Yield (%)
1	none	94	84
2	no $\text{NiBr}_2\text{-glyme}$	—	<1
3	no $(R,R)\text{-L}^*$	—	<1
4	no $\text{K}_3\text{PO}_4\text{-H}_2\text{O}$	—	<1
5	$\text{L1}$ , instead of $(R,R)\text{-L}^*$	—92	84
6	$\text{L2}$ , instead of $(R,R)\text{-L}^*$	—69	26
7	$\text{L3}$ , instead of $(R,R)\text{-L}^*$	—49	33
8	$\text{L4}$ , instead of $(R,R)\text{-L}^*$	—	12
9	$\text{H-SiMe(OEt)}_2$ , instead of $\text{H-Si(OEt)}_3$	94	72
10	5% $\text{NiBr}_2\text{-glyme}$ , 6% $(R,R)\text{-L}^*$	94	75
11	1.5 equiv 1-hexene	94	70
12	2.0 equiv $\text{H-Si(OEt)}_3$ , 2.0 equiv $\text{K}_3\text{PO}_4\text{-H}_2\text{O}$	94	76
13	r.t., instead of $-5\text{ }^\circ\text{C}$	89	74
14	24 h, instead of 40 h	95	62
15	THF, instead of 2-methyl-THF	94	70
16	toluene, instead of 2-methyl-THF	92	82
17	1.0 equiv $\text{H}_2\text{O}$ added	95	78
18	under air (balloon)	94	66

